Drug intelligence / Profile preview

Anti-SFTSV Ab

Development stage: Preclinical
Lead developer: PanGen Biotech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

Anti-SFTSV Ab is a monoclonal antibody being developed by PanGen Biotech for the treatment of Severe Fever with Thrombocytopenia Syndrome (SFTS), a tick-borne viral disease. The antibody is designed to neutralize the SFTS virus (SFTSV), potentially providing a therapeutic option for a condition that currently lacks specific treatment. PanGen Biotech has completed the development of the production cell line and process technology for this candidate. The project is currently in the preclinical stage and is supported by a research service collaboration with the Korea Disease Control and Prevention Agency (KDCA), which is scheduled to continue through April 2025.

Other names: anti-SFTSV antibodymonoclonal antibody against SFTSVSFTSV-monoclonal antibody

Targets

SFTSV Gn (Severe fever with thrombocytopenia syndrome virus glycoprotein Gn)

Beyond the preview

Go deeper on Anti-SFTSV Ab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anti-SFTSV Ab.

Explore the full profile